These results strongly enforce the hypothesis that the increased stabilization of ErbB2 by p130Cas might be a crucial event driving breast cancer progression and resistance to antibody-based anti-ErbB2 therapies, opening new therapeutic alternatives. This evidence concerns the gene ERBB2 and breast carcinoma.